ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Alzamend Neuro's annualized net income for the quarter that ended in Jan. 2024 was $-10.65 Mil. Alzamend Neuro's average Total Stockholders Equity over the quarter that ended in Jan. 2024 was $-3.47 Mil. Therefore, Alzamend Neuro's annualized ROE % for the quarter that ended in Jan. 2024 was N/A%.
The historical rank and industry rank for Alzamend Neuro's ROE % or its related term are showing as below:
ALZN'
s ROE % Range Over the Past 10 Years
Min: -3357.34 Med: -356.05 Max: -160.91
Current: -3357.34
During the past 5 years, Alzamend Neuro's highest ROE % was -160.91%. The lowest was -3,357.34%. And the median was -356.05%.
ALZN's ROE % is ranked worse than 99.56% of 1363
companies
in the Biotechnology industry
Industry Median: -43.82
vs ALZN: -3357.34
Alzamend Neuro ROE % Historical Data
The historical data trend for Alzamend Neuro's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alzamend Neuro's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzamend Neuro's ROE % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzamend Neuro's ROE % distribution charts can be found below:
* The bar in red indicates where Alzamend Neuro's ROE % falls into.
Alzamend Neuro ROE % Calculation
Alzamend Neuro's annualized ROE % for the fiscal year that ended in Apr. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jan. 2024) net income data.
ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
Alzamend Neuro (NAS:ALZN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jan. 2024) net income data. The Revenue data used here is four times the quarterly (Jan. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Alzamend Neuro ROE % Related Terms
Thank you for viewing the detailed overview of Alzamend Neuro's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Alzamend Neuro (Alzamend Neuro) Business Description
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALZN has been successfully added to your 